| abstract |
The present disclosure relates to cleavable conjugates (for example, particle- based or antibody-based conjugates) of TLR7/8 agonists (for example, lH-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating tinker. The present disclosure also related to methods for preparation of the cleavable conjugates, uses thereof for stimulating an effective immune response, and uses thereof for the treatment of cancer. |